Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE 76 versus HYPAQUE M 90.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE 76 versus HYPAQUE M 90.
HYPAQUE-76 vs HYPAQUE-M,90%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
HYPAQUE-76 (diatrizoate meglumine and diatrizoate sodium) is an ionic iodinated contrast agent that attenuates X-rays, providing radiographic contrast. Its mechanism involves high iodine content (76%) that absorbs X-rays, distinguishing anatomical structures in imaging procedures.
Ionic, high-osmolality iodinated contrast agent that absorbs X-rays, enhancing radiographic contrast by attenuating X-rays in tissues where it distributes.
Intravenous: 50-100 mL (as a 76% solution, 370 mg iodine/mL) for contrast imaging, administered as a bolus or infusion; maximum 300 mL per procedure.
Intra-arterial or intravenous injection: 30-60 mL of 90% solution, administered as a bolus or infusion over 1-2 minutes; repeat dosing not recommended.
None Documented
None Documented
Terminal elimination half-life of 1.5-2 hours in normal renal function. Prolonged to >10 hours in moderate renal impairment (CrCl 30-50 mL/min). Closely correlates with creatinine clearance.
Terminal half-life: 1-2 hours (normal renal function); prolonged in renal impairment
Primarily renal; >95% excreted unchanged in urine within 24 hours via glomerular filtration. Fecal excretion minimal (<5%). Biliary excretion negligible.
Renal: >95% unchanged; biliary/fecal: <5%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent